The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 16, 1999
Filed:
Feb. 16, 1996
Derek Lowe, Scotch Plains, NJ (US);
Wei Chang, Livingston, NJ (US);
Joseph Kozlowski, Princeton, NJ (US);
Joel G Berger, Cedar Grove, NJ (US);
Robert McQuade, Scotch Plains, NJ (US);
Allen Barnett, Pine Brook, NJ (US);
Margaret Sherlock, Bloomfield, NJ (US);
Wing Tom, Cedar Grove, NJ (US);
Sundeep Dugar, Bridgewater, NJ (US);
Lian-Yong Chen, Edison, NJ (US);
John W Clader, Cranford, NJ (US);
Samuel Chackalamannil, East Brunswick, NJ (US);
Wang Yuguang, North Brunswick, NJ (US);
Stuart W McCombie, Caldwell, NJ (US);
Jayaram R Tagat, Westfield, NJ (US);
Susan F Vice, Mountainside, NJ (US);
Wayne Vaccaro, Yardley, PA (US);
Michael J Green, Skillman, NJ (US);
Margaret E Browne, Bloomfield, NJ (US);
Theodros Asberom, West Orange, NJ (US);
Schering Corporation, Kenilworth, NJ (US);
Abstract
Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds of formula I ##STR1## wherein one of Y and Z is N and the other is N, CH, or C-alkyl; X is --O--, --SO.sub.0-2 --, amino, substituted amino, --CO--, --CH.sub.2 --, mono or di-substituted methylene, --CS--, --CONR.sup.20 --, --NR.sup.20 --SO.sub.2 --, --NR.sup.20 CO--, --SO.sub.2 NR.sup.20 --, --CH.dbd.CH--, --C.tbd.C-- or --NHC(O)NH--; R is optionally substituted phenyl, aryl or cycloalkyl, or other substituents as defined in the specification; R.sup.1 and R.sup.21 are H, CN or optionally substituted alkyl, or other substituents as defined in the specification; R.sup.2 is optionally substituted cycloalkyl or piperidyl, or other substituents as defined in the specification; and R.sup.3, R.sup.4, R.sup.5, R.sup.20, R.sup.27 and R.sup.28 are as defined in the specification; are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease; pharmaceutical compositions and methods of preparation are also disclosed, as well as synergistic combinations of compounds of the above formula or other compounds capable of enhancing acetylcholine release with acetylcholinesterase inhibitors.